Inogen, Inc. (NASDAQ:INGN) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in Inogen, Inc. (NASDAQ:INGN - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 492,900 shares of the medical technology company's stock after purchasing an additional 75,000 shares during the quarter. Renaissance Technologies LLC owned approximately 2.07% of Inogen worth $4,520,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. AlphaQuest LLC bought a new position in Inogen during the 4th quarter worth about $43,000. Meeder Asset Management Inc. purchased a new position in Inogen during the fourth quarter valued at approximately $56,000. Integrated Quantitative Investments LLC purchased a new position in Inogen during the fourth quarter valued at approximately $92,000. Ieq Capital LLC purchased a new position in Inogen in the fourth quarter valued at about $94,000. Finally, Intech Investment Management LLC bought a new position in shares of Inogen during the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 89.94% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on INGN shares. StockNews.com downgraded Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "hold" rating on shares of Inogen in a research report on Wednesday, April 9th.

Inogen Stock Performance

Shares of INGN traded up $0.11 during trading hours on Friday, hitting $7.26. 110,227 shares of the stock were exchanged, compared to its average volume of 239,347. The stock's 50-day moving average price is $7.65 and its two-hundred day moving average price is $9.07. The company has a market cap of $195.20 million, a price-to-earnings ratio of -3.21 and a beta of 1.48. Inogen, Inc. has a 12-month low of $6.40 and a 12-month high of $13.33.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.